科笛-B(02487)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02487 科笛-B

未开盘 07-06 16:08:30

2.810

+0.070

+2.55%

最高2.880	最低2.680	成交量8,800
今开2.750	昨收2.740	日振幅7.30%
总市值10.48亿	流通市值10.48亿	总股本3.73亿
成交额2.47万	换手率0.00%	流通股本3.73亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02487","market":"HK","secType":"STK","nameCN":"科笛-B","latestPrice":2.81,"timestamp":1783325310577,"preClose":2.74,"halted":0,"volume":8800,"delay":0,"changeRate":0.025547445255474394,"floatShares":373000000,"shares":373000000,"eps":-1.03,"marketStatus":"未开盘","change":0.07,"latestTime":"07-06 16:08:30","open":2.75,"high":2.88,"low":2.68,"amount":24672,"amplitude":0.072993,"askPrice":2.81,"askSize":2800,"bidPrice":2.71,"bidSize":3400,"shortable":0,"etf":0,"ttmEps":-1.009,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1783387800000},"marketStatusCode":0,"adr":0,"listingDate":1686499200000,"exchange":"SEHK","adjPreClose":2.74,"openAndCloseTimeList":[[1783301400000,1783310400000],[1783314000000,1783324800000]],"volumeRatio":0.086139,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02487","defaultTab":"news","newsList":[{"id":"1192638294","title":"科笛-B7月2日因股权激励发行9,803,014股股份，已发行股本增至373,171,291股","url":"https://stock-news.laohu8.com/highlight/detail?id=1192638294","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1192638294?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:19","pubTimestamp":1782998365,"startTime":"0","endTime":"0","summary":"科笛-B(02487)于2026年7月2日发布公告，披露通过首次公开发售前股权激励计划发行新股，涉及合计9,803,014股普通股。其中，因行使受限制股份单位发行792,207股，占本次发行前已发行股本约0.21802%；因行使期权发行9,010,807股，占本次发行前已发行股本约2.4798%。上述股份每股发行价均为USD 0.00002。\n本次发行完成后，公司已发行股份数增至373,171,291股，另持有库藏股1,362,600股，累计已发行及库藏股份总数为374,533,891股。公司在公告中确认，其已遵守所有相关上市规则及法规的要求。\n公告由执行董事张乐乐签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"科笛-B7月2日因股权激励发行9,803,014股股份，已发行股本增至373,171,291股","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648688835","title":"科笛-B(02487)根据股份计划发行980.3万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648688835","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648688835?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:08","pubTimestamp":1782997686,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科笛-B(02487)发布公告，于2026年7月2日根据股份计划发行合计980.3万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1462570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1199572983","title":"科笛-B 2026年6月无新增发行或回购 股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1199572983","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1199572983?lang=zh_cn&edition=full","pubTime":"2026-07-02 21:05","pubTimestamp":1782997553,"startTime":"0","endTime":"0","summary":"科笛集团于2026年7月2日披露了截至2026年6月30日的证券变动月报表，显示公司本月并无新增发行或回购活动，股本结构维持稳定。本月末已发行普通股363,368,277股，库存股份1,362,600股，合计为364,730,877股，与上月底保持一致。公司确认其公众持股量已符合主板上市规则要求。公司同时声明，所有月度内的证券发行事项及库存股份变化均遵循香港联交所《上市规则》和相关法律规定，并经公司董事会正式授权。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648643571","title":"科笛-B创历史新低","url":"https://stock-news.laohu8.com/highlight/detail?id=2648643571","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648643571?lang=zh_cn&edition=full","pubTime":"2026-07-02 13:49","pubTimestamp":1782971396,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2641245193","title":"科笛-B(02487)转仓市值总计9155.84万港元 占比7.07% 从摩根士丹利香港证券转出2572.05万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2641245193","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2641245193?lang=zh_cn&edition=full","pubTime":"2026-06-05 08:16","pubTimestamp":1780618583,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新资料显示，6月4日，科笛-B出现仓位异动，转仓市值总计9155.84万港元，占比7.07%。该公司股东向花旗银行转入2570.61万股，从摩根士丹利香港证券转出2572.05万股。科笛-B发布公告，集团的CU-30101已获得中华人民共和国(中国)国家药品监督管理局药品上市许可。CU-30101是一种用于表皮麻醉手术的局部利多卡因丁卡因复合表皮麻醉乳膏剂。由于其成分的独特药代动力学特性，CU-30101的利多卡因和丁卡因组合配方可产生快速且持久的麻醉效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1450496.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2111349929.HKD","LU0882574139.USD","BK1161","BK4588","IE00BKVL7J92.USD","LU0320765646.SGD","LU1244550494.USD","LU1732800096.USD","LU1791710400.SGD","LU0234570918.USD","LU1668664300.SGD","LU0106261372.USD","LU2487616109.SGD","LU2133065610.SGD","LU0006306889.USD","LU0158827948.USD","LU1363072403.SGD","LU1732799900.SGD","LU0053666078.USD","LU0314104364.USD","LU1989772923.USD","LU0912757837.SGD","LU2089283258.USD","LU1989772840.SGD","LU2089284900.SGD","LU2271345857.HKD","IE00BZ1G4Q59.USD","BK4504","LU0390134368.USD","LU2023251221.USD","02487","LU2357305700.SGD","LU1720051017.SGD","BK4127","LU1548497426.USD","161027","LU1074936037.SGD","LU0158827781.USD","BK4581","BK4516","BK4585","LU0795875086.SGD","LU1988902786.USD","LU0971096721.USD","LU1064131342.USD","LU2028103732.USD","LU2347655156.SGD","LU0528227936.USD","LU0557290698.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1150852905","title":"科笛-B5月股份变动月报表：股本维持稳定","url":"https://stock-news.laohu8.com/highlight/detail?id=1150852905","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1150852905?lang=zh_cn&edition=full","pubTime":"2026-06-04 21:06","pubTimestamp":1780578361,"startTime":"0","endTime":"0","summary":"科笛集团，于2026年6月4日发布截至2026年5月31日的股份变动月报表。公告显示，公司注册股本及已发行股份本月均无变化，整体股本维持稳定。科笛集团注册股本为2,500,000,000股，面值每股0.00002美元，注册股本总额50,000美元，与上月末持平。从披露的期权与股权激励计划看，科笛集团的首次公开发售前股权激励计划及首次公开发售后股权激励计划在本月均未发生新股发行或库存股转让。公司表示，截至2026年5月31日，股本总数保持不变。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635794691","title":"戚薇包贝尔接连“踩坑”，肉毒素赛道何去何从？","url":"https://stock-news.laohu8.com/highlight/detail?id=2635794691","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635794691?lang=zh_cn&edition=full","pubTime":"2026-05-14 16:00","pubTimestamp":1778745600,"startTime":"0","endTime":"0","summary":"日前，演员包贝尔在社交平台自曝注射肉毒素影响工作的话题引发广泛讨论。相关视频中，包贝尔坦言曾为去除（额头）皱纹注射肉毒素，后续却出现额头平整僵硬、眉毛直立的情况，“导演让我表现生气，我明明情绪到位了，但面部毫无表情”，直言这种状况影响演员的职业表现力。这并非个例。去年，著名女演员戚薇在节目中“眼睛变形”的现象也曾引发公众的热烈讨论。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605143737419045.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605143737419045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1153428770","title":"科笛-B发布4月股份变动月报，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1153428770","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1153428770?lang=zh_cn&edition=full","pubTime":"2026-05-07 21:06","pubTimestamp":1778159178,"startTime":"0","endTime":"0","summary":"科笛-B于2026年5月7日披露截至2026年4月30日的证券变动月报表。公告显示，公司注册于开曼群岛，截至本月底法定/注册股本总额维持在USD 50,000，注册股份总数为2,500,000,000股，面值USD 0.00002/股，与上月底一致。本期已发行股份数目为363,368,277股，库存股份1,362,600股，合计364,730,877股，相比上月底无变化。整体来看，科笛-B于本月并未发生新增发行、购回或注销等事项，期末股本规模维持不变。公司在公告中明确表示已遵守香港联交所相关上市规则及法律要求。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633652591","title":"科笛-B(02487)：CU-30101(局部外用利多卡因丁卡因乳膏剂)获国家药监局药品上市许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2633652591","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633652591?lang=zh_cn&edition=full","pubTime":"2026-05-07 06:42","pubTimestamp":1778107379,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科笛-B 发布公告，本集团的CU-30101已获得中华人民共和国(中国)国家药品监督管理局药品上市许可。CU-30101是一种用于表皮麻醉手术的局部利多卡因丁卡因复合表皮麻醉乳膏剂。由于其成分的独特药代动力学特性，CU-30101的利多卡因和丁卡因组合配方可产生快速且持久的麻醉效果。该临床试验结果显示，CU-30101的镇痛疗效与参比制剂 Pliaglis利多卡因丁卡因乳膏相当，且整体安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1438810.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02487","IPOS","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630030689","title":"FIDELITY CHINA SPECIAL SITUATIONS PLC增持科笛-B(02487)3.06万股 每股作价4.6041港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2630030689","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630030689?lang=zh_cn&edition=full","pubTime":"2026-04-28 19:18","pubTimestamp":1777375115,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，香港联交所最新数据显示，4月23日，FIDELITY CHINA SPECIAL SITUATIONS PLC增持科笛-B(02487)3.06万股，每股作价4.6041港元，总金额约为14.09万港元。增持后最新持股数目约为1826.09万股，最新持股比例为5.01%。本交易涉及其他关联方：FIL Limited、Pandanus Associates Inc.、Pandanus Partners L.P.。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1435464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["EWH","02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157538446","title":"科笛-B（02487）2025年收入达3.36亿元 人员与研发投入聚焦皮肤与毛发创新","url":"https://stock-news.laohu8.com/highlight/detail?id=1157538446","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1157538446?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:45","pubTimestamp":1777020329,"startTime":"0","endTime":"0","summary":"科笛-B于本年度实现收入人民币3.36亿元，同比上升20.2%，其中主要产品在毛发疾病与皮肤问题治疗及护理领域带动销售增幅。公司同期毛利约1.96亿元，毛利率提升至58.2%，较上一年度的51.3%明显改善。全年亏损收窄至3.40亿元，同比减少21.6%。管理层将这一结果归因于核心产品的商业化进展、成本控制及运营效率的提升。经营活动现金净流出2.90亿元，较上年同期的4.43亿元进一步收窄，显示公司在费用管控及付款安排方面取得进展。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科笛-B（02487）2025年收入达3.36亿元 人员与研发投入聚焦皮肤与毛发创新","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1174770350","title":"科笛-B授予董事股份购回授权，规模达已发行股本一成","url":"https://stock-news.laohu8.com/highlight/detail?id=1174770350","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1174770350?lang=zh_cn&edition=full","pubTime":"2026-04-24 16:36","pubTimestamp":1777019794,"startTime":"0","endTime":"0","summary":"科笛-B公告显示，公司董事会已提议授予股份购回一般授权，规模最高可达已发行股份总数的10%，即约36,336,827股。公司将于2026年6月26日召开股东大会，审议并表决该项购回计划。董事会认为，适度购回股份可提升每股价值，并可能提高每股收益，符合公司及股东的整体最佳利益。董事会强调，任何购回安排将以保证上市规定要求的公众持股量为前提。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科笛-B授予董事股份购回授权，规模达已发行股本一成","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627481537","title":"港股异动 | 科笛-B(02487)涨超3%  CU-20101（注射用A型肉毒毒素）完成中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2627481537","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627481537?lang=zh_cn&edition=full","pubTime":"2026-04-13 13:37","pubTimestamp":1776058657,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科笛-B(02487)涨超3%，截至发稿，涨3.25%，报4.76港元，成交额40.99万港元。消息面上，科笛今日宣布，集团完成CU-20101（注射用A型肉毒毒素）用于改善中度至重度眉间纹的中国III期临床试验。该临床试验旨在评估CU-20101单次及重复注射治疗中重度眉间纹的有效性和安全性。该临床试验以参比制剂保妥适®注射用A型肉毒毒素（“BOTOX®”）作为对照。该临床试验于2025年11月完成所有受试者出组，并于2026年1月完成数据库锁定且取得积极的顶线结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427621.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4585","BK4588","02487","BK1161","III","BK4134"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627102514","title":"科笛-B(02487)：CU-20101(注射用A型肉毒毒素)用于改善中度至重度眉间纹完成中国III期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2627102514","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627102514?lang=zh_cn&edition=full","pubTime":"2026-04-13 08:18","pubTimestamp":1776039501,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科笛-B 发布公告，本集团完成CU-20101用于改善中度至重度眉间纹的中国III期临床试验。在安全性方面，CU-20101的整体安全性良好，未发生导致提前煺出试验或导致死亡的不良事件，且未发生治疗有关的严重不良事件。CU-20101与BOTOX的安全性评估情况相近，未出现新的安全性信号。CU-20101多次重复注射给药后的有效性及安全性表现与单次用药相似。CU-20101将进一步丰富本集团的皮肤产品矩阵，并有利于与本集团现有产品形成协同效应。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1427503.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","BK1161","02487","III"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141458326","title":"科笛-B更新2026年3月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1141458326","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141458326?lang=zh_cn&edition=full","pubTime":"2026-04-02 21:06","pubTimestamp":1775135198,"startTime":"0","endTime":"0","summary":"科笛集团于2026年4月2日公布截至2026年3月31日的股份变动月报表。公告显示，公司本月无新增发行、回购或注销活动，股本情况保持稳定。公司注册股本为2,500,000,000股普通股，每股面值0.00002美元，总额50,000美元。截至3月31日，已发行股份数量为363,368,277股，库存股份数量为1,362,600股，总计364,730,877股，与上月持平，未发生任何变动。本次月报由执行董事张乐乐签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198502728","title":"科笛-B2025年收益增长20.2%，亏损较上年同期收窄","url":"https://stock-news.laohu8.com/highlight/detail?id=1198502728","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1198502728?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:38","pubTimestamp":1774341535,"startTime":"0","endTime":"0","summary":"截至2025年12月31日止年度，科笛-B的收益约为人民币3.36152亿元，此增幅主要来自毛发疾病及护肤产品销售的提升，并且2025年下半年收益较上半年环比增长约307%。同期销售成本约为1.40360亿元，毛利约1.95792亿元，毛利率由上年度的51%上升至约58%，反映高毛利产品销售贡献增加及持续的成本管控。流动比率由2024年的约2.4倍上升至2025年的约2.9倍，短期偿付能力保持稳健。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621057876","title":"科笛-B(02487)发布年度业绩，股东应占亏损3.4亿元 同比减少21.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621057876","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621057876?lang=zh_cn&edition=full","pubTime":"2026-03-24 16:34","pubTimestamp":1774341256,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科笛-B(02487)发布截至2025年12月31日止年度业绩，该集团取得收益人民币3.36亿元(单位下同)，同比增加20.22%;母公司拥有人应占亏损3.4亿元，同比减少21.58%;每股亏损1.03元。本集团的两款主要产品CU-40102(外用非那雄胺喷雾剂)和CU-10201(外用 4%米诺环素泡沫剂)于2025年10月下旬开始商业化。截至2025年12月31日止年度，两款产品收益合计超过1亿元。本集团持续优化经营效率。截至2025年12月31日止年度，销售及分销、研发及行政开支同比减少约1.09亿元。年内亏损同比减少约9400万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418002.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620413631","title":"科笛-B获富达国际增持179.32万股 每股作价5.01港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620413631","media":"新浪港股","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620413631?lang=zh_cn&edition=full","pubTime":"2026-03-17 08:18","pubTimestamp":1773706680,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　香港联交所最新资料显示，3月11日，富达国际增持科笛-B（02487）179.32万股，每股作价5.01港元，总金额约为898.39万港元。增持后最新持股数目约为1979.26万股，最新持股比例为5.43%。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2026-03-17/doc-inhrfwpy2309284.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","LU0456842615.SGD","SG9999011746.SGD","BK4232","IE00BYTNYN87.SGD","IE00B12V2V27.USD","LU0359201885.HKD","LU0251143458.SGD","LU2247934214.USD","LU0359202008.SGD","LU0327786744.USD","LU0572944931.SGD","BK4022","YMM","LU2242644610.SGD","02487","LU0261950470.USD","BK4539","LU0048575426.USD","LU0455707207.USD","LU0359201612.USD","LU0502904849.HKD","LU1023057109.AUD","BK4526","BK4548","BK4503","IE00BYQNZ168.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619484884","title":"科笛-B(02487)：CU-40104(外用度他雄胺药剂)新药临床试验申请获得国家药监局临床试验默示许可","url":"https://stock-news.laohu8.com/highlight/detail?id=2619484884","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619484884?lang=zh_cn&edition=full","pubTime":"2026-03-16 08:29","pubTimestamp":1773620964,"startTime":"0","endTime":"0","summary":"智通财经APP讯，科笛-B 发布公告，本集团的CU-40104的新药临床试验申请已获得中华人民共和国国家药品监督管理局临床试验默示许可，适应症为治疗雄激素性脱发。本集团正在研发的外用配方可使度他雄胺直接应用于头皮的作用部位，相比口服度他雄胺，预期外用配方可减少全身性暴露及副作用。本集团相信，CU-40104将进一步丰富本集团的毛发疾病产品矩阵，为本集团已获得国家药监局上市批准的CU-40102起到有价值的补充及协同作用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1414072.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"科笛-B(02487)：CU-40104(外用度他雄胺药剂)新药临床试验申请获得国家药监局临床试验默示许可","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02487"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619193903","title":"科笛-B盘中异动 股价大跌6.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619193903","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619193903?lang=zh_cn&edition=full","pubTime":"2026-03-13 15:58","pubTimestamp":1773388736,"startTime":"0","endTime":"0","summary":"2026年03月13日临近收盘15时58分，科笛-B股票出现波动，股价大幅下跌6.07%。截至发稿，该股报4.800港元/股，成交量8.58万股，换手率0.02%，振幅5.87%。资金方面，该股资金流入35.9302万港元，流出6.5758万港元。机构评级方面，在所有1家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。科笛-B股票所在的生物技术行业中，整体跌幅为1.36%。科笛-B公司简介：科笛集团是一家主要从事皮肤学生物制药业务的投资控股公司。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155856a6bcfd59&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260313155856a6bcfd59&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02487","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.cutiatx.com","stockEarnings":[{"period":"1week","weight":0.0148},{"period":"1month","weight":-0.2282},{"period":"3month","weight":-0.4082},{"period":"6month","weight":-0.4031},{"period":"1year","weight":-0.7107},{"period":"ytd","weight":-0.3965}],"compareEarnings":[{"period":"1week","weight":0.0299},{"period":"1month","weight":-0.0891},{"period":"3month","weight":-0.0703},{"period":"6month","weight":-0.1135},{"period":"1year","weight":-0.0299},{"period":"ytd","weight":-0.089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"科笛集团是一家主要从事皮肤学生物制药业务的投资控股公司。该公司致力于皮肤病治疗及护理市场中开发解决方案，涵盖毛发疾病及护理、皮肤疾病及护理、表皮麻醉以及局部脂肪堆积管理。该公司主要从事毛发疾病及护理产品以及若干护肤产品的分销。该公司的主要管线产品包括外用非那雄胺喷雾剂CU-40102、外用4%米诺环素泡沫剂CU-10201、外用新型小分子药剂CU-10101、局部外用利多卡因丁卡因乳膏剂CU-30101和重组突变胶原酶CU-20401。","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.167612},{"month":2,"riseRate":0.666667,"avgChangeRate":0.117769},{"month":3,"riseRate":0.666667,"avgChangeRate":-0.042532},{"month":4,"riseRate":0,"avgChangeRate":-0.028062},{"month":5,"riseRate":0.333333,"avgChangeRate":0.125792},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.095432},{"month":7,"riseRate":0.25,"avgChangeRate":0.076864},{"month":8,"riseRate":1,"avgChangeRate":0.266582},{"month":9,"riseRate":0.333333,"avgChangeRate":-0.056387},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.121205},{"month":11,"riseRate":0,"avgChangeRate":-0.186326},{"month":12,"riseRate":0,"avgChangeRate":-0.277493}],"exchange":"SEHK","name":"科笛-B","nameEN":"CUTIA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"科笛-B(02487)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供科笛-B(02487)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"科笛-B,02487,科笛-B股票,科笛-B股票老虎,科笛-B股票老虎国际,科笛-B行情,科笛-B股票行情,科笛-B股价,科笛-B股市,科笛-B股票价格,科笛-B股票交易,科笛-B股票购买,科笛-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"科笛-B(02487)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供科笛-B(02487)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}